News

New molecular entity: Risedronate sodium delayed-release tablets (Atelvia) were approved for the treatment of postmenopausal osteoporosis

The recently FDA-approved oral direct thrombin inhibitor, dabigatran, may be cost-effective compared to the standard-of-care therapy of adjusted-dose warfarin in patients requiring anticoagulation for stroke prevention in atrial fibrillation, according to a pharmacoeconomic evaluation published in the Annals of Internal Medicine.

With Republicans taking over the House last month and increasing their clout in the Senate, Congressional leaders are contemplating broad federal budget cuts and much more aggressive oversight of administration health policy and regulatory programs.

Recent FDA Approvals (through January 2011) related to Fortesta, Natroba, Abstral, Acetadote, Viibryd, Intelence

Individuals involved in formulary decision-making processes at US health plans were surveyed to determine their current and future use of health economic and outcomes research.

Generic drugs approved by FDA (through January 2011): Fentanyl buccal tablets

This review discusses current contraceptive options including recently approved, newer agents.

Intravenous dolasetron mesylate (Anzemet) should no longer be used to prevent nausea and vomiting associated with cancer chemotherapy in adult or pediatric patients due to an associated dose-dependant increase in QTc prolongation, according to a recent FDA drug safety communication.

Different opioids had different safety profiles when administered to older adults for noncancer pain, according to results from a new study published in the Archives of Internal Medicine.

New indication: Recombinant HPV quadrivalent (types 6, 11, 16, and 18) vaccine (Gardasil) was approved for the prevention of anal cancer and associated precancerous lesions due to HPV in persons aged 9 to 26 years.

This article reviews the emerging class of peripherally acting mu-opioid receptor antagonists and provides insight on formulary considerations when evaluating these agents.

Workers covered by ASOs surpassed the number of workers covered by fully insured arrangements in 2009

Base salaries for top health plan executives increased at the lowest rate in more than a decade

Government agencies will seek to hold not only companies, but also their officers and directors, accountable for lapses in compliance

Insurers must disclose new rates and justify increases that exceed certain thresholds

Adults in the United States are more likely than those in 10 other countries to forgo healthcare due to costs

Nursing home care can be delayed with community services

There are no signs that economic recession is slowing the growth of wellness programs with 74% of employers offering them

Many wonder whether a wave of consolidations will take place as smaller health plans seek economies of scale

As Republication leadership strives to dismantle the law, administration officials are taking steps to protect it

The obvious course of action for managed care organizations might be to take a wait-and-see attitude

Healthcare industry leaders have had to adopt a new way of thinking to prepare for business interruption

What is one thing everyone wants even though no one knows exactly what it is? An accountable care organization.

A former pilot project, Humana Cares has grown its care management abilities

FDA has approved vilazodone HCl tablets (Viibryd, Clinical Data) for the treatment of adults with major depressive disorder.

FDA approved spinosad (Natroba, ParaPRO LLC) Topical Suspension 0.9% for the treatment of head lice infestation in patients aged 4 years and older.

With the healthcare reform law repeal exercise behind them, Congressional leaders can get down to focusing on ways to eliminate or repair some of the more contentious reform provisions and to modify others, according to policy watchers.

FDA has sent MannKind Corp. a complete response letter regarding the company?s NDA for Afrezza Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes for the control of hyperglycemia.

Concern that its potential clot-preventing drug vorapaxar increased the risk of bleeding in stroke victims has prompted Merck & Co. to halt a late-stage study of the drug, the Associated Press reported.

Elderly patients have difficulty with long-term adherence to medications following myocardial infarction, and this is significantly worse among those with kidney dysfunction, according to a study published online January 13 in the Clinical Journal of the American Society of Nephrology, HealthDay News reported.